newsfilter
← Latest News
GlobeNewswire·

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of...